Shares of Inovio Pharmaceuticals Inc.
-1.67%
were up 4.5% in premarket trading on Monday after the company announced a licensing deal with Advaccine Biopharmaceuticals Suzhou Co. Ltd. for its COVID-19 vaccine candidate. As part of the agreement, the privately held Chinese biotech gains exclusive right to develop, manufacture, and commercialize the still-investigational vaccine in China, Hong Kong, Macao, and Taiwan.…
This news comes via ChinaPulse.com, which delivers news, data, analysis, and insights on Chinese business, travel, finance, health, military, investment, and technology.